Home » EU-Wide Guidance Increases Transparency of Marketing Authorization Apps
EU-Wide Guidance Increases Transparency of Marketing Authorization Apps
April 6, 2012
Sponsors, clinical research organizations (CRO) and clinical investigators should have an easier time determining what drug development data in an EU marketing authorization is destined for public consumption, thanks to a new European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) joint guidance.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor